Navigation Links
Drug combo better for common type of metastatic breast cancer, UCI-led study finds
Date:8/1/2012

Irvine, Calif. Postmenopausal women with the most common type of metastatic breast cancer now have a new treatment option that lengthens their lives, according a study led by UC Irvine oncologist Dr. Rita Mehta and conducted by the Southwest Oncology Group. The findings appear in the Aug. 2 issue of the New England Journal of Medicine.

A combination of the two anti-estrogen drugs anastrozole and fulvestrant extended the median survival time of women with Stage 4 hormone receptor-positive metastatic breast cancer by more than six months compared to those who underwent standard treatment with anastrozole alone.

Mehta said the results of the Phase 3 trial are particularly exciting because "these patients have not had a new treatment that gave them an overall survival benefit in more than a decade."

Both drugs are currently used to treat breast cancer, though not in combination. Anastrozole (also known as Arimidex) reduces the production of tumor-promoting estrogen, while fulvestrant (Faslodex) interferes with the receptors that allow estrogen to signal cells to grow and reproduce and also accelerates the degradation of these receptors.

The researchers think it's these modes of action together that make the combination so effective against hormone receptor-positive breast cancer, a subtype that accounts for more than half of all breast cancers.

"The next step would be to try the combination in even earlier stages of breast cancer to see whether long-term cures could be increased at those stages," said Mehta, an associate clinical professor of medicine with the Chao Family Comprehensive Cancer Center and an oncologist with UC Irvine's Breast Health Center.

Study results were first presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium in December. The SWOG S0226 trial was conducted by the SWOG clinical trials network, previously known as the Southwest Oncology Group.


'/>"/>
Contact: Tom Vasich
tmvasich@uci.edu
949-824-6455
University of California - Irvine
Source:Eurekalert

Page: 1

Related medicine news :

1. Experimental Chemo Combo for Colon Cancer Disappoints
2. Value of Metformin, Insulin Combo for Type 2 Diabetes Questioned
3. Two-Drug Combo Helps Teens With Migraines
4. Two-Drug Combo May Be Safe for Melanoma Treatment
5. Breast cancer clinical trial tests combo of heat shock protein inhibitor and hormonal therapy
6. Combo Therapy May Help Ease Ringing in the Ears
7. FDA Approves Combo Shot for Meningitis, Hib in Kids
8. Booze, Energy Drinks, Casual Sex Combo Common in College: Study
9. A better tool to diagnose tuberculosis
10. Job injuries among youth prompt calls for better safety standards
11. Students focus on creating a better cervical collar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... ... September 26, 2017 , ... Your World Insurance Services, ... 2017 and began fulfilling a life-long wish of owner Stacy Boyle to give back ... recipient of help when I was in high school,” said Ms. Boyle. “My father ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... student Ashlea Grabau. The $1000 student scholarship is awarded each semester to a ... to Ashlea Grabau who is a medical student at Arizona State University with ...
(Date:9/25/2017)... (PRWEB) , ... September 25, 2017 , ... ... the first and only fully programmable fall detection smart watch. VitalBand provides ... many critical contacts as you want so help arrives quickly. Plus, it’s ...
(Date:9/25/2017)... ... 2017 , ... The Coleman Institute, a leader in opioid ... Minneapolis-St. Paul, MN, Dr. Adam Locketz. Dr. Locketz will be offering a full ... his Timewise Medical practice in the twin cities. , Dr. Locketz graduated ...
(Date:9/25/2017)... ... 2017 , ... The Renal Support Network (RSN) is proud to announce the ... rich content focused on RSN’s mission to empower people who have kidney disease to ... , Our unique website is loaded with hundreds of exclusive personal stories. These ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... INDIANAPOLIS , Sept. 7, 2017  Eli ... today announced actions to streamline operations to more ... to improve its cost structure. Global workforce reductions, ... program, are expected to impact approximately 3,500 positions. ... the company expects annualized savings of approximately $500 ...
(Date:9/7/2017)... Sept. 7, 2017   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade cell and tissue hypothermic storage ... Mike Rice , President and CEO, will be presenting ... Rodman & Renshaw 19 th Annual Global Investment ... (12:25 p.m. Pacific time). The conference is being held at ...
(Date:9/6/2017)... Eli Lilly and Company (NYSE: ... for galcanezumab and lasmiditan, two investigational treatments for migraine, ... (IHC) taking place Sept. 7-10 in Vancouver ... long-term data from an open-label study evaluating the safety ... and 240 mg) for the prevention of migraine. Galcanezumab ...
Breaking Medicine Technology: